Antipsychotics: impact on prolactin levels

REFERENCES

• SCHATZBERG AF, NEMEROFF CB: Textbook of Psychopharmacology American Psychiatric Press, Washington DC, USA (1998).
   Google Scholar
• SACHAR EJ, GRUEN PH, ALTMAN N, HALPERN FS, FRANTZ AG: Use of neuroendocrine techniques in psychopharmacological research. In: Hormones, Behavior, and Psychopathology Sachar EJ (Ed.), Raven Press, New York, USA (1976):161–176.
   Google Scholar
• SACHAR EJ, GRUEN PH, ALTMAN N, LANGER G, HALPERN FS: Prolactin responses to neuroleptic drugs: an approach to the study of brain dopamine blockade in humans. In: Neuroregulators and Psychiatric Disorders. Usdin E (Ed.) Oxford University Press, New York, USA (1977):242.
   Google Scholar
• ••Interesting early paper that attempted touse prolactin blockade as model for therapeutic response in psychosis.
   Google Scholar
• RUBIN RT: Strategies of neuroendocrine research in psychiatry. In: Neuroregulators and Psychiatric Disorders. Usclin E (Ed.) Oxford University Press, New York, USA (1977):233–241.
   Google Scholar
• CLARK D, HJORTH S, CARLSSON A: Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. theoretical considerations. Neural Transm. (1985) 62:171–207.
   PubMed Web of Science ®Google Scholar
• SACHAR EJ, GRUEN PH, KARASU TB, ALTMAN N, FRANTZ AG: Thioridazine stimulates prolactin secretion in man. Arch. Gen. Psychiatry (1975) 32:885–886.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, SACHAR EJ, FRANTZ AG: Dopamine antagonism by thioridazine in schizophrenia. Biel Psychiatry(1975) 10:53–57.
   PubMedGoogle Scholar
• ••Interesting early paper on impact ofconventional antipsychotics on prolactin.
   Google Scholar
• MELTZER HY, FANG VS: The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch. Gen. Psychiatry (1976) 33:279–286.
   PubMed Web of Science ®Google Scholar
• GRUEN PH, SACHAR EJ, LANGER G et al.: Prolactin responses to neuroleptics in normal and schizophrenic patients. Arch. Gen. Psychiatry (1978) 35:108–116.
   PubMed Web of Science ®Google Scholar
• ••Interesting paper indicating broad-based effect of almost all antipsychotics on prolactin concentrations.
   Google Scholar
• LYKOURAS L, MARKIANOS M, HATZIMANOLIS J, OULIS P, CHRISTODOULOU GN: Prolactin secretion in response to haloperidol challenge in delusional (psychotic) and non-delusional depression. Eric Psychiatry (2000) 15:480–482.
   PubMed Web of Science ®Google Scholar
• COHEN-MANSFIELD J, TAYLOR L, WOOSLEY R, LIPSON S, WERNER P, BILLIG N: Relationships between psychotropic drug dosage, plasma drug concentration, and prolactin levels in nursing home residents. Thec Drug Monit. (2000) 22:688–694.
   PubMedGoogle Scholar
• CHOU J C-Y, DOUYON R, CZOBOR P, VOLAVKA J, COOPER TB: Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Res. (1998) 81:51–55.
   PubMedGoogle Scholar
• KOLAKOWKSA T, BRADDOCK L, WILES D, FRANKLIN M, GELDER M: Neuroendocrine tests during treatment with neuroleptic drugs: I. Plasma prolactin response to haloperidol challenge. Br. J. Psychiatry (1981) 139:400–412.
   PubMedGoogle Scholar
• BLOOM FE, KUPFER DJ: Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, USA (1995).
   Google Scholar
• SCHMIDT AW, LEBEL LA, JOHNSON CG: The novel antipsychotic ziprasidone has a unique human receptor binding profile compared to other agents. Soc. Nerosci. Abs. (1998) 24(2):2177.
   Google Scholar
• Bristol-Myers Squibb, Data on file.
   Google Scholar
• TURRONE P, KAPUR S, SEEMAN MV, FLINT AJ: Elevation of prolactin levels by atypical antipsychotics. Am. J. Psychiatry (2002) 159:133–135.
   PubMed Web of Science ®Google Scholar
• ••Interesting recent paper showing thatatypicals can produce short-term increase in prolactin.
   Google Scholar
• PRETORIUS JL, PHILLIPS M, LANGLEY RW, SZABADI E, BRADSHAW CM: Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Br. J. Clin. Pharmacol (2001) 52:322–326.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, GOODE DJ, SCHYVE PM, YOUNG M, FANG VS: Effect of clozapine on human serum prolactin levels. Am. J. Psychiatry (1979) 136:1550–1555.
   PubMed Web of Science ®Google Scholar
• BREIER AF, MALHOTRA AK, SUT-P et al.: Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry (1999) 156:294–298.
   PubMed Web of Science ®Google Scholar
• WUDARSKY M, NICOLSON R, HAMBURGER SD et al.: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Child Adelesc. Psychepharmacel (1999) 9:239–245.
   PubMed Web of Science ®Google Scholar
• MELTZER HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacol (Berlin) (1989) 99:S18–S27.
   Google Scholar
• CARACCI G: Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. Clin. Psychopharmacol (1999) 19:194–196.
   PubMed Web of Science ®Google Scholar
• MARKIANOS M, HATZIMANOLIS J, LYKOURAS L: Dopamine receptor responsitivity in schizophrenic patients before and after switch from haloperidol to risperidone. Psychiatry Res. (1999) 89:115–122.
   PubMed Web of Science ®Google Scholar
• ••This paper is important as it shows anincrease in prolactin after switching from a conventional to an atypical antipsychotic.
   Google Scholar
• DAVID SR, TAYLOR CC, KINON BJ, BREIER A: The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. The]: (2000) 22:1085–1096.
   PubMed Web of Science ®Google Scholar
• KEARNS AE, GOFF DC, HAYDEN DL: Risperidone-associated hyperprolactinemia. Endoc. Pract. (2000) 6:425–429.
   PubMedGoogle Scholar
• DANIELS GH, HAYDEN DL, GOFF DC, KEARNS AE: Effect of risperidone dose on serum prolactin level. Ender.. Pract. (2001) 7:224.
   PubMedGoogle Scholar
• KLEINBERG DL, DAVIS JM, DE COSTER R, VAN BAELEN B, BRECHER M: Prolactin levels and adverse events in patients treated with risperidone. Psychopharmacol (1999) 19:57–61.
   Google Scholar
• ANANTH JV, BURGOYNE KS, SMITH MW: Prolactin levels in patients taking risperidone and ziprasidone. American Psychiatric Association Annual Meeting. New Orleans, LA, USA (5–10 May 2001) 104:42-43. Syllabus and Proceedings Summary.
   Google Scholar
• ESEL E, BASTURK M, GONUL AS, et al.: Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Psychoneumendocrinol (2001) 26:641-647. 1385 Expert Op/n. Pharmacother. (2002) 3(1 0)
   Google Scholar
• CRAWFORD AMK, BEASLEY CM JR, TOLLEFSON GD: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Res. (1997) 26:41–54.
   PubMedGoogle Scholar
• BEASLEY CM JR, TOLLEFSON G, TRAN P, SATTERLEE W, SANGER T, HAMILTON S, OLANZAPINE HGAD STUDY GROUP: Olanzapine versus placebo and haloperidol: acute results of the North American double-blind olanzapine trial. Neuropsychopharmacol (1996) 14:111–123.
   PubMedGoogle Scholar
• KAPUR S, ZIPURSKY R, JONES C, SHAMMI CS, REMINGTON G, SEEMAN P: A positron emission tomography study of quetiapine in schizophrenia. Arch. Gen. Psychiatry (2000) 57:553–559.
   PubMed Web of Science ®Google Scholar
• HAMNER MB, AVANITIS LA, MILLER BG, LINK CGG, HONG WW: Plasma prolactin in schizophrenia treated with Seroquel (ICI 204,636). Psychopharmacol Bull. (1996) 32:107–110.
   PubMed Web of Science ®Google Scholar
• ARVANITIS LA, MILLER BG, SEROQUEL TRIAL 13 STUDY GROUP: Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophenia: A comparison with haloperidol and placebo. Biol. Psychiatry (1997) 42:233–246.
   PubMed Web of Science ®Google Scholar
• SMALL JG, HIRSCH SR, ARVANITIS LA: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatry (1997) 54:549–557.
   PubMed Web of Science ®Google Scholar
• KING DJ, LINK CGG, KOWALCYK B: A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacol (1998) 137:139–146.
   Google Scholar
• ••Interesting as prolactin fell from baselinein a large population at both low and high doses of quetiapine.
   Google Scholar
• BORISON RL, ARVANITIS LA, MILLER BG: ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. j Clin. Psychopharmacol (1996) 16:158–169.
   PubMed Web of Science ®Google Scholar
• DANIEL DG, WIEDEN PJ, O'SULLIVAN RL: Improvement in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone. American Psychiatric Association Annual Meeting, Chicago, IL, USA (13–18 May 2000).
   Google Scholar
• GOFF DC, POSEVER T, HERZ L, et al: An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J. Clin. Psychopharmacol (1998) 18:296–304.
   PubMed Web of Science ®Google Scholar
• CARSON WH, STOCK E, SAHA AR, et al: Meta-analysis of safety and tolerability with aripiprazole. Schizophrenia Res. (2002) 53(3, Suppl.):86.
   Google Scholar
• CASEY DE, SAHA AR, ALI MW, JODY et al.: Switching to aripiprazole monotherapy. American Psychiatric Association Annual Meeting. Philadelphia, PA, USA (18–23 May 2002).
   Google Scholar
• VERBEECK WJ, BERK M, PALKERJ, JERSKY B: The prolactin response to sulpiride in major depression. Eur. Neuropsychopharmacol (2001) 11:215–220.
   PubMedGoogle Scholar
• KONDO T, MIHARA K, YASUI N, et al.: Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin. j Clin. Psychopharmacol (2000) 20:404–409.
   Google Scholar
• MELKERSSON KI, HULTING A-L, PANE AJ: Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br. J. Clin. Pharmacol (2001) 51:317–324.
   PubMed Web of Science ®Google Scholar
• MAGUIRE GA: Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences. Clin. Psychiatry (2002) 63 (Suppl. 4):56–62.
   Google Scholar
• BAPTISTA T, LACRUZ A, MEZA T, et al: Antipsychotic drugs and obesity: Is prolactin involved? Can. J. Psychiatry(2001) 46:834.
   Google Scholar
• HADAD PM, HELLE WELL JSE, WIECKA: Antipsychotic induced hyperprolactinemia: A series of illustrative case reports. J. Psychopharmacol (2001) 4:293–296.
   Google Scholar